

# **DOLPHIN MEDICAL SERVICES LIMITED**

#417, Sanali Heavens, Ameerpet, HYDERABAD – 500 073, Telangana, India  
Phone/Fax:+91-40-23738877, Email: [dolphinmedicalindia@gmail.com](mailto:dolphinmedicalindia@gmail.com)  
[www.dolphinmedicalservices.com](http://www.dolphinmedicalservices.com), CIN:L24239TG1992PLC014775

---

Date: 13.02.2019

To  
The Manager  
Department of Corporate Services  
**BOMBAY STOCK EXCHANGE LTD.**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
**MUMBAI - 400 001.**

Dear Sir,

Sub: **Submission of Unaudited Financial Results for the 3<sup>rd</sup> Quarter and Nine months ended 31.12.2018 along with the Limited Review Report – Reg.**

Ref: Our letter dated 06.02.2019

With reference to the above and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are herewith submitting the Unaudited Financial Results for the 3<sup>rd</sup> Quarter and Nine months ended 31.12.2018 along with the Limited Review Report.

Kindly take it on your records.

Thanking You Sir

Yours faithfully  
for **DOLPHIN MEDICAL SERVICES LIMITED**



**NANAPANENI BUDDHA SAGAR**  
Director

Encl.s:

1. Unaudited Financial Results for the 3<sup>rd</sup> Quarter and Nine months ended 31.12.2018
2. Limited Review Report for the Quarter ended 31.12.2018

# DOLPHIN MEDICAL SERVICES LIMITED

# 417, SANALI HEAVENS, AMEERPET, HYDERABAD - 500 073, TELANGANA

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2018**


CIN: L24239TG1992PLC014775, email: dolphincomplianceofficer@gmail.com

(Prepared in compliance with the Indian Accounting Standards (Ind AS))

(Amount Rs. in Lakhs)

Sl. No.	PARTICULARS	QUARTER ENDED 31.12.2018 UNAUDITED	QUARTER ENDED 30.09.2018 UNAUDITED	QUARTER ENDED 31.12.2017 UNAUDITED	NINE MONTHS ENDED 31.12.2018 UNAUDITED	NINE MONTHS ENDED 31.12.2017 UNAUDITED	FINANCIAL YEAR ENDED 31.03.2018 AUDITED
1	<b>Revenue from Operations</b>						
	Revenue from Operations	1.57	1.74	3.72	6.00	12.39	15.32
	Other Income	1.94	2.00	3.14	5.90	6.64	9.25
	<b>Total Revenue (I + II)</b>	<b>3.51</b>	<b>3.74</b>	<b>6.86</b>	<b>11.90</b>	<b>19.03</b>	<b>24.57</b>
2	<b>Expenses</b>						
a	Cost of Materials consumed	0.65	0.72	0.87	2.20	2.82	3.71
b	Purchases of stock-in-trade	--	--	--	--	--	--
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	--	--	--	--	--	--
d	Employee benefit expense	0.95	0.95	0.85	2.77	2.79	3.66
e	Finance costs	0.23	0.26	0.27	0.74	0.79	1.05
f	Depreciation and amortisation expense	7.67	8.36	8.36	24.38	25.07	33.43
g	Other Expenses	7.06	2.64	2.24	11.77	14.22	16.19
	<b>Total expenses</b>	<b>16.56</b>	<b>12.93</b>	<b>12.59</b>	<b>41.86</b>	<b>45.69</b>	<b>58.04</b>
3	<b>Profit/(Loss) before exceptional items and tax</b>	<b>(13.05)</b>	<b>(9.19)</b>	<b>(5.73)</b>	<b>(29.96)</b>	<b>(26.66)</b>	<b>(33.47)</b>
4	Exceptional items	--	--	--	--	--	--
5	<b>Profit/(Loss) before tax</b>	<b>(13.05)</b>	<b>(9.19)</b>	<b>(5.73)</b>	<b>(29.96)</b>	<b>(26.66)</b>	<b>(33.47)</b>
6	<b>Tax Expense</b>						
7	Current tax	--	--	--	--	--	--
8	Deferred tax	--	--	--	--	--	(3.68)
9	<b>Total tax expenses</b>	--	--	--	--	--	<b>(3.68)</b>
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	--	--	--	--	--	--
11	<b>Net Profit/(Loss) for the period from continuing operations</b>	<b>(13.05)</b>	<b>(9.19)</b>	<b>(5.73)</b>	<b>(29.96)</b>	<b>(26.66)</b>	<b>(29.79)</b>
12	Profit (loss) from discontinued operations before tax	--	--	--	--	--	--
13	Tax expense of discontinued operations	--	--	--	--	--	--
14	Net Profit/(Loss) for the period from discontinued operations after Tax	--	--	--	--	--	--
15	<b>Net Profit/(Loss) for the period</b>	<b>(13.05)</b>	<b>(9.19)</b>	<b>(5.73)</b>	<b>(29.96)</b>	<b>(26.66)</b>	<b>(29.79)</b>
16	Other comprehensive income net of taxes	--	--	--	--	--	--
17	<b>Total Comprehensive Income/(Loss) for the period</b>	<b>(13.05)</b>	<b>(9.19)</b>	<b>(5.73)</b>	<b>(29.96)</b>	<b>(26.66)</b>	<b>(29.79)</b>
18	<b>Details of equity share capital</b>						
	Paid-up equity share capital	1,509.99	1,509.99	1,509.99	1,509.99	1,509.99	1,509.99
	Face value of equity share capital	10.00	10.00	10.00	10.00	10.00	10.00
19	<b>Reserves excluding revaluation reserve</b>	--	--	--	--	--	<b>(290.81)</b>
	Debenture redemption reserve	--	--	--	--	--	--
20	<b>Earnings per equity share for continuing operations</b>						
	Basic earnings (loss) per share from continuing operations	(0.09)	(0.06)	(0.04)	(0.20)	(0.18)	(0.20)
	Diluted earnings (loss) per share from continuing operations	(0.09)	(0.06)	(0.04)	(0.20)	(0.18)	(0.20)

By Order of the Board  
for DOLPHIN MEDICAL SERVICES LIMITED

  
NANAPANENI BUDDHA SAGAR  
Director

21	<b>Earnings per equity share for discontinued operations</b>						
	Basic earnings (loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
	Diluted earnings (loss) per share from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
22	<b>Earnings per equity share</b>						
	Basic earnings (loss) per share from continuing and discontinued operations	(0.09)	(0.06)	(0.04)	(0.20)	(0.18)	(0.20)
	Diluted earnings (loss) per share from continuing and discontinued operations	(0.09)	(0.06)	(0.04)	(0.20)	(0.18)	(0.20)
23	<b>Public Share Holding:</b>						
	i) Number of Shares	11,107,651	11,107,651	11,107,651	11,107,651	11,107,651	11,107,651
	ii) Percentage of Share Holding	73.56%	73.56%	73.56%	73.56%	73.56%	73.56%
24	<b>Promoters and Promoter group</b>						
	Share holding						
	a) Pledged/Encumbered						
	- Number of Shares	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a %age of total share holding of promoter and promoter group)	N.A	N.A	N.A	N.A	N.A	N.A
	- Percentage of shares (as a %age of total share capital of the company)	N.A	N.A	N.A	N.A	N.A	N.A
	b) Non-encumbered						
	- Number of Shares	3,992,301	3,992,301	3,992,301	3,992,301	3,992,301	3,992,301
	- Percentage of shares (as a %age of total share holding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shares (as a %age of total share capital of the company)	26.44%	26.44%	26.44%	26.44%	26.44%	26.44%

Particulars	Quarter ended 31st December 2018
<b>B Investor Complaints</b>	
1 Pending at the beginning of the Quarter	NIL
2 Received during the quarter	2
3 Disposed off during the quarter	2
4 Remaining unresolved at the end of the quarter	NIL

NOTES :

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 13th February 2019.
- The company has adopted Indian Accounting Standards (Ind AS) prescribed under Sec. 133 of the Companies Act, 2013 read with the relevant rules issued thereunder, from April 1, 2017 accordingly these unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" and other accounting principles generally accepted in India.

Place: Hyderabad  
Date : 13.02.2019

By Order of the Board  
for DOLPHIN MEDICAL SERVICES LIMITED

*N. B. Sagar*

NANAPANENI BUDDHA SAGAR

Director

**LIMITED REVIEW REPORT ON THE QUARTERLY RESULTS OF M/s. DOLPHIN MEDICAL SERVICES LIMITED FOR THE QUARTER and NINE MONTHS ENDED 31<sup>ST</sup> DECEMBER 2018**

Review Report to  
The Board of Directors  
**M/s. Dolphin Medical Services Limited**  
#417, Sanali Heavens, Ameerpet  
**HYDERABAD – 500 073**

We have reviewed the accompanying statement of Unaudited Financial Results of M/s. Dolphin Medical Services Limited for the quarter and nine months ended 31<sup>st</sup> December 2018 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their Board Meeting has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for **PINNAMANENI & Co.,**  
Chartered Accountants  
(Firm Registration No.002661S)

**CA P.V.V. SATYANARAYANA**  
Partner  
Membership No. 26600

Hyderabad  
13.02.2019

